Amycretin

Mechanism

Amycretin is a next-generation weight loss peptide from Novo Nordisk that activates both GLP-1 and amylin receptors in a single molecule. This dual action suppresses appetite through two complementary pathways — GLP-1 slows gastric emptying and enhances insulin release, while amylin acts on the brainstem to reduce hunger. Early trials show potentially greater weight loss than semaglutide alone.

Evidence

• Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives.

  Fu L et al. (2026) — Metabolism — PMID: 41850421

  Indexed review summarizes amycretin mechanism and emerging clinical efficacy in obesity, useful as a synthesis source while the direct evidence base remains early-phase and sponsor-led.

  moderate

• Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.

  Gasiorek A et al. (2025) — Lancet — PMID: 40550229

  First-in-human randomized placebo-controlled study found oral amycretin generally safe and tolerable in overweight/obesity, with dose-proportional pharmacokinetics and mostly mild-to-moderate gastrointestinal adverse events supporting continued development.

  strong

• Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.

  Dahl K et al. (2025) — Lancet — PMID: 40550231

  Phase 1b/2a randomized study in 125 participants with overweight/obesity found substantial placebo-adjusted weight loss with weekly subcutaneous amycretin, reaching -24.3% at 60 mg over 36 weeks, with gastrointestinal adverse events mostly mild to moderate.

  strong